Clinical Trial Update: A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on SRP-9004 (patidistrogene bexoparvovec) evaluating safety in LGMD2D; study phases 1/2 have completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-girdle Muscular Dystrophy Type 2d

Drugs mentioned

• SRP-9004

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Limb-Girdle Muscular Dystrophy, Type 2D | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-04-01